TheragenEtex Comes in Second Place at “Dream Challenge,” an International Competition for Precision Medicine
On April 1, Theragen Bio (CEO and President Samuel(Taesoon) Hwang) announced that it came in place second at the Pancancer Drug Activity Dream Challenge, an international competition for precision medicine.
Many international researchers, academics, and businesspeople participate in each challenge. The competition is recognized as highly authoritative in precision medicine as its progress or outcomes are published in major cancer societies or SCI papers.
This event was hosted by the US non-profit organization Sage Bionetworks, Columbia University Irving Medical Center from the US, Icahn School of Medicine at Mount Sinai from the US, and Heidelberg University School of Medicine from Germany.
The theme of the challenge is different every time. This time, the theme was to predict the target of a drug by applying the cancer research data provided by Columbia University, which required drug repositioning based on AI.
Young big data researchers from Theragen Etex participated and came in second place in the Sub-challenge 1. This achievement proved the company’s high precision in drug target prediction by using genome data analysis, bioinformatics, and AI, which it has been built up over the past 10 years.